
The aim of this study was to evaluate the zzso and long-term safety of zzso in patients with Crohn's disease in clinical zzso 

The medical records of 500 consecutive patients treated with zzso at the Mayo Clinic were reviewed and zzso for demographic features and adverse zzso The likelihood of a zzso relationship to zzso for each adverse event was determined by calculating an intrinsic likelihood zzso zzso 

The 500 patients received a median of 3 infusions and had a median follow-up of 17 zzso zzso patients zzso experienced a serious adverse event, of which 30 zzso were related to zzso Acute infusion reactions occurred in 19 of 500 patients zzso zzso zzso disease occurred in 19 of 500 patients and was attributed to zzso in 14 zzso Three patients developed drug-induced zzso One patient developed a new zzso zzso Forty-eight patients had an infectious event, of which 41 zzso were attributed to zzso Twenty patients had a serious zzso 2 had fatal zzso 8 had pneumonia (of which 2 cases were zzso 6 had viral infections, 2 had abdominal zzso requiring surgery, one had arm zzso and one had zzso Nine patients had a zzso disorder, 3 of which were possibly related to zzso A total of 10 deaths were zzso For 5 of these patients zzso the events leading to death were possibly related to zzso 

zzso and long-term zzso therapy is generally well zzso However, clinicians must be vigilant for the occurrence of zzso but serious events, including serum zzso reaction, opportunistic infection and zzso and zzso zzso 

